| LRRK2 | Decrease LRRK2 kinase
activity | Denali—DNL-151 | Phase 1 | NCT04056689 |
| Denali—DNL-201 | Phase 1 | NCT03710707 |
| Glucocerebrosidase | Chemical chaperone to
translocate mutant enzyme
from the endoplasmic
reticulum into lysosomes | Ambroxol | Phase 2 | NCT02941822 and NCT02914366 |
| Allergan—LTI-291 | Phase 1 | Netherlands Trial NL7061 |
Block accumulation of the
glucocerebrosidase
substrate, glucosylceramide | Genzyme/Sanofi—Ibiglustat
(GZ/SAR40267) | Phase 2 | NCT02906020 |
| α-Synuclein | Anti–α-synuclein monoclonal
antibodies to lower
α-synuclein concentrations
and block cell-to-cell
transmission | Biogen—Cinpanemab | Phase 1/2 | NCT03318523 and NCT03716570 |
Hoffmann–La Roche/Prothena—
Prasinezumab | Phase 2 | NCT03100149 |
| Abbvie—ABBV 0805 | Phase 1 | NCT04127695 |
| Takeda/AstraZeneca—MEDI1341 | Phase 1 | NCT03272165 |
| Lundbeck—Lu-AF-82422 | Phase 1 | NCT03611569 |
Inhibitors of pathological
α-synuclein aggregation | Enterin—ENT-01 | Phase 1 | NCT03938922 |
Alterity Therapeutic—
PBT434 | Phase 1 | U1111–1211-0052 |
Neuropore Therapies Inc./UCB
S.A.—NPT200-11 | Phase 1 | NCT02606682 |
| c-Abl kinase | c-Abl kinase inhibition | SPARC—K0706 | Phase 2 | NCT03655236 |
| Novartis—Nilotinib | Phase 2 | NCT02954978 and NCT03205488 |
| 1ST Biotherapeutics, Inc—FB-101 | Phase 1 | NCT04165837 |
| GLP-1 receptor | GLP-1 receptor agonist,
decreases inflammation | Amylin Pharmaceutical/
AstraZeneca—Exenatide | Phase 3 | NCT03456687,
NCT04154072, and
ISRCTN14552789 |
| Novo Nordisk—Liraglutide | Phase 2 | NCT02953665 |
| Sanofi—Lixisenatide | Phase 2 | NCT03439943 |
| Neuraly—NLY01 | Phase 2 | NCT04154072 |
